IGF1 and acromegaly: The two parameters of biochemical control, suppression of excess GH secretion to predefined threshold levels and normalization of serum IGF-1 levels, are used as the primary markers of efficacy in most clinical trials of somatostatin analogues in patients with acromegaly.